Licht-Murava, A., Paz, R., Vaks, L., Avrahami, L., Plotkin, B., Eisenstein, M., & Eldar-Finkelman, H. A unique type of GSK-3 inhibitor brings new opportunities to the clinic. 2016. Science Signaling.

Grieco, S. F., Velmeshev, D., Magistri, M., Eldar-Finkelman, H., Faghihi, M. A., Jope, R. S., & Beurel, E. Ketamine up-regulates a cluster of intronic miRNAs within the serotonin receptor 2C gene by inhibiting glycogen synthase kinase-3. 2016. The World Journal of Biological Psychiatry.

Grieco, S. F., Cheng, Y., Eldar-Finkelman, H., Jope, R. S., & Beurel, E. Up-regulation of insulin-like growth factor 2 by ketamine requires glycogen synthase kinase-3 inhibition. 2016. Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Aloni, E Shapira, M., Eldar-Finkelma, H., Barnea, A. GSK-3β inhibition affects singing behavior and neurogenesis in adult songbirds. Brain, Behavior and Evolution. 2015. in press.

Azoulay-Alfaguter I, Elya R, Avrahami L, Katz A, Eldar-Finkelman H. Combined regulation of mTORC1 and lysosomal acidification by GSK-3 suppresses autophagy and contributes to cancer cell growth. 2014. Oncogene.

Avrahami L, Licht-Murava A, Eisenstein M, Eldar-Finkelman H. GSK-3 inhibition: Achieving moderate efficacy with high selectivity. 2013. Biochim Biophys Acta.

Avrahami L, Farfara D, Shaham-Kol M, Vassar R, Frenkel D, Eldar-Finkelman H. Inhibition of glycogen synthase kinase-3 ameliorates ?-amyloid pathology and restores lysosomal acidification and mammalian target of rapamycin activity in the Alzheimer disease mouse model: in vivo and in vitro studies. 2013. J Biol Chem.

Lo Monte F, Kramer T, Gu J, Brodrecht M, Pilakowski J, Fuertes A, Dominguez JM, Plotkin B, Eldar-Finkelman H, Schmidt B. Structure-based optimization of oxadiazole-based GSK-3 inhibitors. 2013. Eur J Med Chem.

Licht-Murava A, Eldar-Finkelman H.Exploiting substrate recognition for selective inhibition of protein kinases.2012. Curr Pharm Des.

Lo Monte F, Kramer T, Gu J, Anumala UR, Marinelli L, La Pietra V, Novellino E, Franco B, Demedts D, Van Leuven F, Fuertes A, Dominguez JM, Plotkin B, Eldar-Finkelman H, Schmidt B. Identification of glycogen synthase kinase-3 inhibitors with a selective sting for glycogen synthase kinase-3alpha. 2012. J Med Chem.

Eldar-Finkelman H, Martinez A. GSK-3 inhibitors: preclinical and clinical focus on CNS. 2011. Front Mol Neurosci.

Monte FL, Kramer T, Bol?nder A, Plotkin B, Eldar-Finkelman H, Fuertes A, Dominguez J, Schmidt B. Synthesis and biological evaluation of glycogen synthase kinase 3 (GSK-3) inhibitors: an fast and atom efficient access to 1-aryl-3-benzylureas. 2011. Bioorg Med Chem Lett.

Alon LT, Pietrokovski S, Barkan S, Avrahami L, Kaidanovich-Beilin O, Woodgett JR, Barnea A, Eldar-Finkelman H. Selective loss of glycogen synthase kinase-3alpha in birds reveals distinct roles for GSK-3 isozymes in tau phosphorylation. 2011. FEBS Lett.

Licht-Murava A, Plotkin B, Eisenstein M, Eldar-Finkelman H. Elucidating Substrate and Inhibitor Binding Sites on the Surface of GSK-3β and the Refinement of a Competitive Inhibitor. 2011. J Mol Biol.

Azoulay-Alfaguter I, Yaffe Y, Licht-Murava A, Urbanska M, Jaworski J, Pietrokovski S, Hirschberg K, Eldar-Finkelman H. Distinct molecular regulation of GSK-3alpha isozyme controlled by its N-terminal region. Functional role in calcium/calpain signaling. 2011. J. Biol. Chem.

Karyo R, Askira Y, Pinhasov A, Belmaker H, Agam G, Eldar-Finkelman H. Identification of eukaryotic elongation factor-2 as a novel cellular target of lithium and glycogen synthase kinase-3. 2010, Mol Cell Neurosci.

Eldar-Finkelman, H., Licht-Murava A, Pietrokovski S, Eisenstein M. Substrate Competitive GSK-3 Inhibitors- Strategy and Implications. 2009, Biochim. Biophys. Acta.

Shruster A, Eldar-Finkelman H, Melamed E, Offen D. Wnt signaling pathway overcomes the disruption of neuronal differentiation of neural progenitor cells induced by oligomeric amyloid beta-peptide. J Neurochem. 2011 Feb;116(4):522-9. doi: 10.1111/j.1471-4159.2010.07131.x. Epub 2011 Jan 24.

Leng S, Zhang W, Zheng Y, Liberman Z, Rhodes CJ, Eldar-Finkelman H, Sun XJ. Glycogen synthase kinase 3 beta mediates high glucose-induced ubiquitination and proteasome degradation of insulin receptor substrate 1. J Endocrinol. 2010 Aug;206(2):171-81. Epub 2010 May 13.

Watson RL, Spalding AC, Zielske SP, Morgan M, Kim AC, Bommer GT, Eldar-Finkelman H, Giordano T, Fearon ER, Hammer GD, Lawrence TS, Ben-Josef E. GSK3beta and beta-catenin modulate radiation cytotoxicity in pancreatic cancer. Neoplasia. 2010 May;12(5):357-65.

Eldar-Finkelman, H., Eisenstein, M. Peptides Inhibitors Targeting Protein Kinases. 2009, Current Pharmaceutical Design. 15(21):2463-70.

Ilouz, R, Pietrokovsky, S, Eisenstein, M, Eldar-Finkelman, H. 2008, New Insights into the Autoinhibition Mechanism of Glycogen Synthase Kinase-3β. J. Mol. Biol. 385:999-1007.

Liberman Z. Plotkin, B. Eldar-Finkelman, H., 2008, Coordinated Phosphorylation of Insulin receptor Substrate-1 by Glycogen Synthase Kinase-3 and Protein Kinase C3βII at in the Diabetic fat Tissue. 2008, Am. J. Physiol. Endocrinol. Metab. 294:E1169-1177.

Caspi, M., Zilberberg , A. Eldar-Finkelman, H., Rosin-Arbesfeld, R. Nuclear GSK-3beta inhibits the canonical Wnt signalling pathway in a beta-catenin phosphorylation-independent manner. 2008, Oncogene. 27:3546-3555.

Sharfi, H. Eldar-Finkelmnan, H. 2007, Sequential Phosphorylation of Insulin Receptor Substrate-2 by Glycogen Synthase Kinase-3 and c-Jun N-Terminal Kinase Plays a Role in Hepatic Insulin Signaling Am. J. Physiol. Endocrinol. Metab.

Erez A, Castiel A, Trakhtenbrot L, Perelman M, Rosenthal E,Goldstein I, Stettner N, Harmelin A, Eldar-Finkelman H, Campaner S, Kirsch I, Izraeli S. 2007, The SIL Gene Is Essential for Mitotic Entry and Survival of Cancer Cells. Cancer Res. 67:4022-4027.

Shapira, M. Licht, A. Milman, A. Pick,C.G., Shohami, E. Eldar-Finkelman, H. 2007. Role of Glycogen Synthase Kinase-3β in Early Depressive Behavior Induced by Mild Traumatic Brain Injury. Mol. Cell. Neuroscience. 34:571-577.

Ilouz, R., Kowalsman, N., Eisenstein, M., Eldar-Finkelman, H. 2006 Identification of Novel Glycogen Synthase Kinase-3β Substrate Interacting Residues Suggests A Common Mechanism For Substrates Recognition. J. Biol. Chem. 281:30621-30.

Kaidanovich-Beilin, O., Eldar-Finkelman, H. 2006, Peptides Targeting Protein Kinases-Strategies and Implicatiosn. Physiology, 21:411-8.

Kaidanovich-Beilin, O. and Eldar-Finkelman, H. 2006 Long-Term Treatment with Novel Glycogen Synthase Kinase-3 Inhibitor Improves Glucose Homeostasis in Ob/Ob Mice: Molecular Characterization In Liver And Muscle. J. Pharmacol. Exp. Ther. 316:17-24.

Liberman Z. and Eldar-Finkelman H. 2005, Serine332 Phosphorylation of Insulin Receptor Substrate-1 by Glycogen Synthase Kinase-3 Attenuates Insulin Signaling. J. Biol. Chem. 280:4422-8.

Tailor, I. Tennenbaum , T., Kuroki, T. Eldar-Finkelman, H. 2005, Protein Kinase C-δ Dependent Activation of Oxidative Stress In Adipocytes of Insulin Resistant and Obese Mice: role for NADPH oxidase. Am. J. Physiol. Endocrinol. Metab. 288:E405-11.

Kirshennboim, N., Plotkin, B., Ben Shlomo, S., Kaidanovich-Beilin, O., Eldar-Finkelman, H. 2004, Lithium-mediated phosphorylation of glycogen synthase kinase-3 involves PI3 Kinase-dependent activation of protein kinase C-α. J. Mol. Neuroscience, 24, 199-207.

Kaidanovich-Beilin, O., Milman, A., Pick, C., Weizman, A., Eldar-Finkelman, H. 2004, Rapid anti-depressive like activity of specific GSK-3 inhibitor, and its effect on β-catenin in the mouse hippocampus. Biol. Psychiatry, 55:781-784.

Eldar-Finkelman, H. Ilouz, R. 2003, Challenges and opportunities with glycogen synthase kinase-3 inhibitors in treatment of insulin resistance and type 2 diabetes, Expert Opin. Invs. Drug, 2003, 12 1511-1519.

Eldar-Finkelman, H. Ilouz, R. 2003, Challenges and opportunities with glycogen synthase kinase-3 inhibitors in treatment of insulin resistance and type 2 diabetes, Expert Opin. Invs. Drug, 2003, 12 1511-1519.

Plotkin B., Kaidanovich, O., Talior, I. Eldar-Finkelman, H. 2003 Insulin mimetic action of synthetic phosphorylated peptide inhibitors of glycogen synthase kinase-3. J. Pharmacol. Exp. Ther. Section- molecular and cellular. 305:974-980

Kaidanovich-Beilin, O., Eldar-Finkelman, H. 2002, The role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes. Expert. Opin. Ther. Targ.; 6:555-561.

Ilouz, R., Kaidanovich, O., Gurwitz, D., Eldar-Finkelman, H. 2002 Inhibition of glycogen synthase kinase-3β by bivalent zinc ions: insights into the insulin-mimetic action of zinc. Biochem. Biophys. Res. Commun. 295:102-106.

Gurwitz, D. Eldar-Finkelman, H. 2002, GSK-3 inhibitors: potential drugs for neurodegenerative disorders. Drug Discovery Today; 6: 1072-1074.

Eldar-Finkelman, H. 2002, Glycogen synthase kinase-3: an emerging therapeutic target. Trends Mol. Med; 8:126-132.

Hall, J.L., Chatham, J.C., Eldar-Finkelman H., Gibbons, H. 2001 Upregulation of glucose metabolism during intimal lesion formation is coupled to the inhibition of vascular smooth muscle cell apoptosis: role of GSK-3β. Diabetes; 50:1171-9.

Zhao, A.Z., Shinohara, M.M., Huang, D., Shimizu, M., Eldar-Finkelman, H. Krebs, E.G., Beavo, J.V., Bornfeldt, K.E. 2000, Leptin induces insulin-like signaling that antagonizes cAMP elevation by glucagon in hepatocytes. J. Biol. Chem.; 275:11348-54.